GGrantIndex
Sort

1,049,261 grants matching t cell

Mechanisms of Atherogenesis in Insulin Resistance

$1,985,122
Ira A Tabas · Columbia University Health Sciences · P01 · FY2018 · HL

NK Cells, Their Receptors and Unrelated Donor Transplant

$1,985,078
Jeffrey S Miller · University Of Minnesota · P01 · FY2006 · CA

AAV Gene Therapy for Lipid Disorders

$1,985,074
James M Wilson · University Of Pennsylvania · P01 · FY2016 · HL

The impact of changes in chromatin architecture on cancer phenotypes and tumor progression

$1,984,949
Jane Amanda Skok · New York University School Of Medicine · P01 · FY2022 · CA

The impact of changes in chromatin architecture on cancer phenotypes and tumor progression

$1,984,949
Jane Amanda Skok · New York University School Of Medicine · P01 · FY2023 · CA

Augmented Injury due to Autologous Inflammatory Attack

$1,984,881
Francis D Moore · Brigham And Women'S Hospital · P50 · FY2009 · GM

Characterization of in vivo neuronal and inter-neuronal responses to transcranial focused ultrasound

$1,984,876
Bin He · Carnegie-Mellon University · R01 · FY2021 · NS

Mapping the vulnerable locus coeruleus pathways in aging and AD

$1,984,794
Kwanghun Chung · Massachusetts Institute Of Technology · U01 · FY2022 · AG

Studies of Joint Aging and Osteoarthritis

$1,984,784
Martin K. Lotz · Scripps Research Institute, The · P01 · FY2016 · AG

TAS::89 0211::TAS RECOVERY ACT: PHASE III XLERATOR PROGRAM- ELECTRODEPOSITED MN-CO ALLOY COATING FOR SOLID OXIDE FUEL CELL INTERCONNECTS

$1,984,784
Faraday Technology, Inc. · · FY2010 · Department of Energy

Transgenic resources for neuroscience research

$1,984,775
James Pickel · National Institute Of Mental Health · ZIC · FY2014 · MH

High Performance Computing for Biomedical Research

$1,984,664
Joel R. Stiles · Carnegie-Mellon University · P41 · FY2006 · RR

First-in-Human (Phase 1) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's Disease (AD)

$1,984,624
Eti Yoles · Immunobrain Checkpoint Inc. · R01 · FY2021 · AG

Cytopathology Core

$1,984,623
Armando Filie · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA

IGF::OT::IGF R&D- NANOEMULSION FORMULATION AND IND-ENABLING STUDIES OF A NOVEL CENTER STEM CELL CYTOTOXIC AGENT

$1,984,617
James Egan · Targagenix, Inc. · N44 · FY2016 · CA

Host-tumor cell interaction in myeloma: therapeutic applications

$1,984,614
Kenneth C Anderson · Dana-Farber Cancer Inst · P01 · FY2011 · CA

Duke SPORE in Brain Cancer

$1,984,462
John H Sampson · Duke University · P50 · FY2020 · CA

Liquid biopsy and radiomics for liver cancer surveillance

$1,984,454
Bachir Taouli · Icahn School Of Medicine At Mount Sinai · U01 · FY2025 · CA

EFRI-HyBi: Lignin Deconstruction for the Production of Liquid Fuels

$1,984,322
Rodney J Andrews · University Of Kentucky Research Foundation · · FY2009 · ENG

Longitudinal validation of retinal biomarkers against cerebral imaging in preclinical Alzheimer's disease

$1,984,309
Jessica Alber · University Of Rhode Island · R01 · FY2025 · AG

Genes and signals controlling mammalian hematopoiesis.

$1,984,290
Paul E Love · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2017 · HD

Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity

$1,984,196
Ofer Levy · Boston Children'S Hospital · U19 · FY2019 · AI

Genomic Resource for the Yeast Saccharomyces

$1,984,127
Joe Michael Cherry · Stanford University · U41 · FY2020 · HG

The Arterial Wall and Atherogenesis in Mice and Humans

$1,984,094
Columbia University Health Sciences · P50 · FY2005 · HL

ADULT AIDS CLINICAL TRIALS UNIT

$1,984,093
Indiana Univ-Purdue Univ At Indianapolis · U01 · FY2001 · AI